- Axsome Therapeutics sees a pivotal win with its ADHD drug, solriamfetol, in Phase 3 trials.
- Analyst optimism remains high with an impressive average price target suggesting substantial growth potential.
- GuruFocus estimates further underscore the attractive valuation upside for AXSM investors.
Axsome Therapeutics (AXSM, Financial) has announced promising results from a Phase 3 clinical trial for its ADHD medication, solriamfetol. The trial demonstrated significant enhancements in symptom control and overall disease severity compared to a placebo, showcasing a remarkable 45% reduction in the Adult ADHD Investigator Symptom Rating Scale. Importantly, solriamfetol was well-tolerated with no reports of serious side effects.
Optimistic Analyst Projections
Wall Street analysts present a positive outlook for Axsome Therapeutics Inc (AXSM, Financial). With one-year price targets from 17 experts, the average anticipated price stands at $177.47, with projections ranging from a high of $216.00 to a low of $148.00. This average target represents a substantial upside of 80.83% compared to its current market price of $98.14. Investors can explore more detailed estimate data on the Axsome Therapeutics Inc (AXSM) Forecast page.
Consensus Shows Strong Confidence
The consensus recommendation from 18 brokerage firms aligns with an "Outperform" status for Axsome Therapeutics Inc (AXSM, Financial), as evidenced by the current average brokerage recommendation of 1.7. The rating scale, where 1 signifies a Strong Buy and 5 denotes a Sell, underscores the confidence analysts have in the stock.
GuruFocus Analysis Highlights Significant Potential
According to GuruFocus estimates, Axsome Therapeutics Inc (AXSM, Financial) holds a projected GF Value of $252.05 within one year, indicating a potential upside of 156.83% from its current price of $98.14. GF Value represents GuruFocus's estimation of the fair stock value, calculated based on historical trading multiples, past business growth, and future performance projections. For further detailed analysis, visit the Axsome Therapeutics Inc (AXSM) Summary page.
